INVO Bioscience, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- INVO Bioscience, Inc. (NASDAQ: INVO) operates as a commercial-stage fertility company that provides assisted reproductive technology (ART) solutions worldwide. The company offers its flagship INVOcell device, a patented medical product enabling intravaginal culture (IVC) for the natural incubation of eggs and sperm during fertilization and early embryo development as an alternative to traditional in vitro fertilization (IVF) and intrauterine insemination (IUI); the related INVO procedure, which supports in vivo embryo growth within the woman's body to enhance accessibility, reduce costs by approximately 50% compared to standard IVF, and deliver comparable pregnancy rates; and professional aesthetic solutions under INVO Aesthetics powered by BioBlend Technology, featuring growth factors and exosomes for skin and hair rejuvenation treatments used by medical professionals. INVO Bioscience maintains dedicated INVO Centers for IVC procedures, with three operational in North America, and sells its technology through distributors, IVF clinics, and physicians targeting infertility patients seeking more natural, cost-effective options. Founded in 2007 and headquartered in Sarasota, Florida, the company conducts geographic operations across the United States, Canada, Latin America, Europe, Asia including Thailand, the Middle East, and Africa. Recent developments include record second-quarter 2024 financial results with 481% revenue growth and a $1.1 million improvement in adjusted EBITDA; the termination of its proposed merger with NAYA Biosciences after multiple amendments and extensions; and ongoing national expansion through clinic acquisitions to enhance clinical capabilities and broaden access to innovative fertility care in the Midwest and beyond.
Why INVO Fertility Stock Is Surging Friday Afternoon
INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q
INVO Fertility Announces Fiscal Year 2025 Financial Results
INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic
INVO Fertility's Wisconsin Clinic Joins Progyny Network
INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility Announces Patent Issuance for Modified INVOcell® Device
INVO Fertility Issues Shareholder Letter Highlighting Strengthened Fundamental Position and Strategic Outlook for Growth
INVO Fertility to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
INVO Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on November 28, 2025
INVO Fertility Announces Third Quarter 2025 Financial Results
INVO Fertility Partners with Heidi Health to Bring AI-Powered Tools to INVO's Wisconsin Fertility Institute
INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
INVO Fertility Announces Second Quarter 2025 Financial Results